Labiotech.eu

News and Trends 3 Jun 2015

Poor topline results for NeuroVive’s CicloMulsion Phase III

Phase III is a critical step in a drug development process. NeuroVive Pharmaceutical has learned this the hard way. The Swedish company reported unsatisfactory results of CicloMulsion’s phase III clinical trial in patients having gone through a specific type of heart attack known as STEMI (ST-segment elevation acute myocardial infarction). The disappointing topline results are expected to […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Jun 2015

Avantium’s bioplastic, latest Green Hope for the Agribusiness?

After many awards and famous collaborations, the Dutch biotech company Avantium signed a deal with Tereos for the production of its 100% biobased plastic. The Bioplastic provider is moving forward to disrupt an established market! Initially created as a spin off of Shell, Avantium is a 15 years old Dutch company specialized in the area of advanced […]

June 3, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 3 Jun 2015

Keregen: Winner of the world’s largest Biotech Start-up Accelerator!

OneStart 2015, the world’s largest life sciences and health care startup accelerator program has just rewarded Keregen from the UK with €137.8K (£100K) and Ligadon with €134.6K ($150K) for respectively winning OneStart Europe and OneStart Americas. So, who is this promising European upcomer? Keregen, based in London, develops first-in-class medicines for the prevention and treatment of neurodegenerative […]

June 3, 2015 - 2 minutesmins - By Alexandre Lowrey

News and Trends 2 Jun 2015

Genticel aims to prevent Cancer caused by the Human Papillomavirus

Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002’s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform. Vaxiclase is a technology platform that can be used with many antigens in several […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

After Failing Phase III, Active Biotech is back to square one

Unfortunately, the Biotech world is not only composed of success stories. Active Biotech, a Swedish company focused on developing treatments for neurodegenerative diseases and cancer. The company, engaged with Ipsen, discontinued a Phase III study and is currently discovering the consequences of this failure the hard way. Active Biotech’s business model, like many small red biotechs, is based on partnering with […]

June 2, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 2 Jun 2015

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Immuno-oncology has gone from a competition to a battlefield. Bristol-Meyer Squibb launched a lawsuit against David Berman, a former researcher that abruptly quit last month after 10 years working for the company’s cancer R&D division. Berman, with his deep knowledge about BMS’s immune-oncology research, headed to AstraZeneca, BMS’ principal opponent. Game on. In this competitive […]

June 2, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 2 Jun 2015

Will Glowee Replace Electric Lighting with Bioluminescent Bacteria?

What if we could use less electricity to light today’s civilizations? Glowee is a French start-up willing to take on this challenge by using genetically modified bacteria to produce light. I had the chance to talk with the company’s CEO Sandra Rey and will give you my thoughts. It all started from a student project in a design college. Back […]

June 2, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 1 Jun 2015

DNA Therapeutics presents positive results for its breakthrough Advanced Cancer Therapy

ASCO Annual Meeting keeps bringing positive results of European companies that cross the ocean to present their clinical trial outcomes. DNA Therapeutics, the French biopharma, presented the results of the first-in-man phase I/IIa trial of DT01 in patients with cutaneous metastatic melanoma. Cancer cells can easily repair themselves after damage incurred in their DNA from […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

Eisai receives Europe’s OK for its Thyroid Cancer treatment

Lenvatinib, Eisai’s treatment of thyroid cancer, has received the marketing authorization of the European Commission. The Japanese company is increasing its European presence with Lenvatinib, an orally administered molecular-targeted agent. Lenvatinib, commercially sold under the name Lenvima, is a designated orphan drug in Japan, the United States and in Europe for the treatment of people with […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

Private investors have finally backed Mapi Pharma’s project with €9.1M. Shavit Capital has led the Series A financing round to support the company’s clinical development plans. The cash raised is sufficient to advance the company’s lead product Glatiramer Acetate (GA) Depot to its Phase III. The Israeli company has a bitter record of failed NASDAQ […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

CRISPR technology receives the Spanish ‘Nobel prize’

CRISPR continues to amass prizes and to consolidate itself as the biggest discovery of the century. Its discoverers received last Wednesday the Princess of Asturias Award of Technical and Scientific Research. Emmanuel Charpentier and Jennifer Doudna, who shared the prize, received €50k. The prize was established in 1980 and consists in a series of annual prizes […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 31 May 2015

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

The big pharma companies Eli Lilly and AstraZeneca will combine two of their cancer drugs to make the perfect cocktail against solid tumors. They have entered a clinical collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor (MEDI4736), in combination with Cyramza (ramucirumab), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. MEDI4736 is […]

May 31, 2015 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Poor topline results for NeuroVive’s CicloMulsion Phase III

Avantium’s bioplastic, latest Green Hope for the Agribusiness?

Keregen: Winner of the world’s largest Biotech Start-up Accelerator!

Genticel aims to prevent Cancer caused by the Human Papillomavirus

After Failing Phase III, Active Biotech is back to square one

Immuno-oncology race gets bloodier: BMS is suing its former executive now working for AstraZeneca

Will Glowee Replace Electric Lighting with Bioluminescent Bacteria?

DNA Therapeutics presents positive results for its breakthrough Advanced Cancer Therapy

Eisai receives Europe’s OK for its Thyroid Cancer treatment

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

CRISPR technology receives the Spanish ‘Nobel prize’

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!